Latest News

  • REGULATORY

    12 Mar 2026

    Moderna's Flu Vaccine Clears a Regulatory Hurdle

  • INNOVATION

    6 Mar 2026

    Beta Cells Get a New Line of Defense

  • TECHNOLOGY

    4 Mar 2026

    The Tiny Carriers Powering mRNA’s Next Leap

  • INSIGHTS

    2 Mar 2026

    A Single Jab for Flu and COVID? EU Says Yes

Layered Nanoparticles Boost mRNA Delivery

Researcher using microscope to analyze samples in laboratory

INNOVATION

25 Feb 2026

Core-shell lipid nanoparticles show early gains in mRNA release but raise new design and safety questions

Syringe labeled Moderna mRNA-3927 with Recordati logo in background

PARTNERSHIPS

10 Feb 2026

Moderna and Recordati Bet on mRNA Beyond Vaccines

Moderna and Recordati partner on an mRNA therapy for propionic acidemia, combining resources to accelerate development

mRNA vaccine vial on medical documents with pills, syringe, and stethoscope

MARKET TRENDS

5 Feb 2026

mRNA Deals Push the Industry Beyond Vaccines

Big acquisitions and delivery breakthroughs signal mRNA’s shift from pandemic speed to precision therapies

BioNTech and CureVac company branding displayed outside offices

PARTNERSHIPS

3 Feb 2026

BioNTech–CureVac Deal Marks a New Era for mRNA

BioNTech’s CureVac buyout shows how scale and integration are now driving competition in the mRNA industry

Biotech executives mark a major corporate milestone during a Nasdaq ceremony

PARTNERSHIPS

20 Jan 2026

GSK’s $2.2B Bet Signals a New Phase in Allergy Drug Races

GSK’s acquisition of RAPT spotlights late-stage allergy drugs, hints at a cautious M&A revival, and raises the stakes in immunology

Bristol Myers Squibb corporate sign outside company campus

INSIGHTS

19 Jan 2026

BMS–Orbital Deal Signals a Sharper Bet on In Vivo RNA

Bristol Myers Squibb’s Orbital buy shows how big pharma is methodically building RNA muscle beyond vaccines

Merck and Moderna logos displayed on a white background

RESEARCH

16 Jan 2026

mRNA Developers Regroup After Trial Setbacks

After late-stage failures, mRNA leaders narrow pipelines, double down on vaccines and cancer, and adopt tougher capital discipline

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.